Spinal Muscular Atrophy: Current Medications and Re-purposed Drugs

Area of Science:

• Neurology
• Genetics
• Pharmacology

Background:

• Spinal muscular atrophy (SMA) is a severe autosomal recessive genetic neuromuscular disorder.
• Characterized by progressive muscle weakness and atrophy due to alpha motor neuron degeneration.
• Current effective treatments remain limited, necessitating alternative therapeutic strategies.

Purpose of the Study:

• To review repurposed drugs demonstrating efficacy in treating spinal muscular atrophy (SMA).
• To evaluate the current drug repurposing strategies for SMA.
• To emphasize the need for a systematic approach in developing SMA therapeutics.

Main Methods:

• Literature review of existing studies on drug repurposing for SMA.
• Identification and analysis of repurposed drugs including branaplam, riluzole, olesoxime, harmine, and prednisolone.
• Assessment of the systematicity and approach in current drug repurposing strategies.

Main Results:

• Several repurposed drugs, such as branaplam, riluzole, olesoxime, harmine, and prednisolone, have shown potential in improving SMA.
• Current drug repurposing for SMA often relies on serendipity rather than organized methodologies.
• The development of effective SMA interventions is hindered by the lack of systematic approaches.

Conclusions:

• Drug repurposing is a viable strategy to accelerate the development of SMA treatments.
• A methodical, systematic approach targeting SMA's molecular basis is crucial for faster therapeutic breakthroughs.
• Future research should focus on structured drug repurposing to overcome current limitations.